Fosphenytoin sodium hydrate
CAS: 92134-98-0
Ref. 3D-FF23601
11mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued | ||
250mg | Discontinued |
Product Information
- 5,5-Diphenyl-3-[(phosphonooxy)methyl]-2,4-imidazolidinedione sodium hydrate
- 2,4-Imidazolidinedione, 5,5-diphenyl-3-[(phosphonooxy)methyl]-, disodium salt
- 2,4-Imidazolidinedione, 5,5-diphenyl-3-[(phosphonooxy)methyl]-, sodium salt (1:2)
- Acc 9653
- Acc 9653-010
- Cetebyx
- Ci 982
- Disodium (2,5-Dioxo-4,4-Diphenylimidazolidin-1-Yl)Methyl Phosphate
- Fostoin
- Pro-Epanutin
- See more synonyms
- Fosphenytoin sodium
Fosphenytoin is a water-soluble drug that is used in the treatment of seizures. It is a prodrug that undergoes hydrolysis to phenytoin, its active form. Fosphenytoin sodium hydrate (FSN) has been shown to have immunomodulatory effects and may be used as an adjuvant therapy for autoimmune diseases and infectious diseases. FSN has been shown to inhibit voltage-dependent calcium channels in leukocytes, which may contribute to its therapeutic effects. The pharmacokinetic properties of FSN have been studied using both analytical methods and computer modeling techniques. In vitro studies have shown that FSN can be incorporated into polymeric matrices as well as nutrient solutions without altering its therapeutic efficacy, making it a suitable carrier for parenteral administration.